Adjunctive Pharmacotherapy for Cognitive Deficits in Schizophrenia

by Life Mental Health

Adjunctive pharmacotherapy for cognitive deficits in schizophrenia
To investigate the comparative efficacy of these agents on cognition and symptoms in schizophrenia, and to identify promising cognitive domains and candidate medications that can be incorporated in treatment trials combined with cognitive remediation … Read more on British Journal of Psychiatry

Intra-Cellular Therapies Announces Closing of Million Private Placement …
Proceeds from the private placement will be used for the development of the Company's drug candidates including its lead drug candidate, ITI-007, which is being studied in a Phase II clinical trial for the treatment of schizophrenia. Sharon Mates, CEO … Read more on PR Newswire (press release)